Lactate Dehydrogenase in Hypertensive Disorders in Pregnancy: Severity or Diagnosis Marker?

Background: Lactate dehydrogenase has had an exciting journey as a utility marker in different illnesses, but currently, its clinical utility has been relegated to confirm hemolysis, as a tumor marker, and as a diagnostic biomarker of preeclampsia. The findings of lactate dehydrogenase concentrations taking reference values to healthy persons are not consistent when these are related to hypertensive disorders in pregnancy, mainly to begin symptoms or little severity presentation. The goal in this work was to evaluate the maternal serum concentration of lactate dehydrogenase and its utility as a severity or diagnosis marker for hypertensive disorders in pregnancy. Methods: In this retrospective study, we included 5,558 cases of HDP and 800 healthy pregnancies. HDP classification and LD values were collected from the medical records in the paper chart. Results: The prevalence of HDP in our hospital was approximately 6.4 ± 0.1%. We found a tendency toward increases in median LD concentrations with the increasing severity of HDP and found a positive correlation (p = 0.037) or error probability of 0.037% between LD concentrations and severity of HDP in Mexican pregnant women. Conclusion: Serum LD concentration in HDP is a marker of severity, diagnosis and adverse maternal outcomes.